PHAXIAM Therapeutics SA (PHXM)

US29604W2070 - ADR

3.1  -0.02 (-0.64%)

After market: 3.1 0 (0%)

Fundamental Rating

2

Overall PHXM gets a fundamental rating of 2 out of 10. We evaluated PHXM against 568 industry peers in the Biotechnology industry. PHXM has a bad profitability rating. Also its financial health evaluation is rather negative. PHXM has a expensive valuation and it also scores bad on growth.



2

1. Profitability

1.1 Basic Checks

PHXM had negative earnings in the past year.
PHXM had a negative operating cash flow in the past year.

1.2 Ratios

The Return On Assets of PHXM (-0.35%) is better than 93.60% of its industry peers.
PHXM has a better Return On Equity (-0.62%) than 93.94% of its industry peers.
Industry RankSector Rank
ROA -0.35%
ROE -0.62%
ROIC N/A
ROA(3y)-57.41%
ROA(5y)N/A
ROE(3y)-170.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PHXM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

2

2. Health

2.1 Basic Checks

PHXM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PHXM remains at a similar level compared to 1 year ago.
PHXM has a better debt/assets ratio than last year.

2.2 Solvency

PHXM has an Altman-Z score of -1.09. This is a bad value and indicates that PHXM is not financially healthy and even has some risk of bankruptcy.
PHXM has a Altman-Z score of -1.09. This is comparable to the rest of the industry: PHXM outperforms 52.36% of its industry peers.
A Debt/Equity ratio of 0.30 indicates that PHXM is not too dependend on debt financing.
PHXM has a worse Debt to Equity ratio (0.30) than 71.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Altman-Z -1.09
ROIC/WACCN/A
WACC4.88%

2.3 Liquidity

PHXM has a Current Ratio of 1.78. This is a normal value and indicates that PHXM is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.78, PHXM is not doing good in the industry: 80.13% of the companies in the same industry are doing better.
PHXM has a Quick Ratio of 1.78. This is a normal value and indicates that PHXM is financially healthy and should not expect problems in meeting its short term obligations.
PHXM's Quick ratio of 1.78 is on the low side compared to the rest of the industry. PHXM is outperformed by 78.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 99.68% over the past year.
PHXM shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.04%.
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1025.16%
Revenue 1Y (TTM)59.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-70.86%

3.2 Future

PHXM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.84% yearly.
Based on estimates for the next years, PHXM will show a very negative growth in Revenue. The Revenue will decrease by -18.92% on average per year.
EPS Next Y77.73%
EPS Next 2Y36.72%
EPS Next 3Y23.84%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%

3.3 Evolution

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHXM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHXM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PHXM's earnings are expected to grow with 23.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.72%
EPS Next 3Y23.84%

0

5. Dividend

5.1 Amount

PHXM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PHAXIAM Therapeutics SA

NASDAQ:PHXM (3/8/2024, 8:27:22 PM)

After market: 3.1 0 (0%)

3.1

-0.02 (-0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)03-20 2024-03-20/amc
Inst Owners0.01%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.83M
Analysts85
Price Target10.17 (228.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.8%
PT rev (3m)6.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-15.5%
EPS NY rev (3m)-0.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.6
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 2.87
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-4.14
FCFYN/A
OCF(TTM)-4.12
OCFYN/A
SpS1.19
BVpS6.57
TBVpS1.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.35%
ROE -0.62%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.41%
ROA(5y)N/A
ROE(3y)-170.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.3
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.21%
Cap/Sales 1.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z -1.09
F-Score3
WACC4.88%
ROIC/WACCN/A
Cap/Depr(3y)10.07%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.01%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1025.16%
EPS Next Y77.73%
EPS Next 2Y36.72%
EPS Next 3Y23.84%
EPS Next 5YN/A
Revenue 1Y (TTM)59.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-70.86%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-18.92%
EBIT growth 1Y51.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.84%
EBIT Next 3Y11.18%
EBIT Next 5YN/A
FCF growth 1Y44.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.05%
OCF growth 3YN/A
OCF growth 5YN/A